Literature DB >> 16045658

Renal effects of hypotensive anaesthesia in combination with acute normovolaemic haemodilution with hydroxyethyl starch 130/0.4 or isotonic saline.

C Fenger-Eriksen1, C Hartig Rasmussen, T Kappel Jensen, E Anker-Møller, J Heslop, J Frøkiaer, E Tønnesen.   

Abstract

BACKGROUND: Hypotensive anaesthesia (HA) and acute normovolaemic haemodilution (ANH) are used separately to decrease per-operative blood loss. Reducing blood viscosity by adding ANH to HA may appear profitable in a situation with lowered perfusion pressure and concern about organ ischemia. The aim of this study was to clarify the influence of HA in combination with ANH using crystalloid or colloid as replacement fluid on renal function.
METHODS: Hypotensive anaesthesia was induced in 11 patients referred to major spine surgery using sevoflurane in combination with fentanyl/remifentanil. Acute normovolaemic haemodilution was carried out by drawing venous blood into standard blood bags and replacing it by isotonic saline 0.9% (Group S) or HES 130/0.4 (Group V). Renal function was evaluated before, during and up to 8 h after hypotension as the glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) by means of 51Cr-EDTA and 125I-Hippuran clearances.
RESULTS: Lowering mean arterial blood pressure decreased GFR and ERPF in both groups. During hypotension ERPF was lower in Group S (n = 5) than Group V (n = 6). Renal function was normalized postoperatively. We found a positive but non-significant correlation between the relative GFR change and the duration of hypotension.
CONCLUSION: In conclusion, our study demonstrated that renal function, assessed by GFR and ERPF, is transiently reduced during the combination of hypotensive anaesthesia and acute normovolaemic haemodilution. A colloid-based fluid regime (HES 130/0.4) used for haemodilution may preserve renal function to a greater extent than a crystalloid-based regime (0.9% saline).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045658     DOI: 10.1111/j.1399-6576.2005.00714.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?

Authors:  Christiane S Hartog; Frank M Brunkhorst; Christoph Engel; Andreas Meier-Hellmann; Maximilian Ragaller; Tobias Welte; Evelyn Kuhnt; Konrad Reinhart
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

2.  The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality.

Authors: 
Journal:  Intensive Care Med       Date:  2011-02-10       Impact factor: 17.440

3.  Are all colloids same? How to select the right colloid?

Authors:  Sukanya Mitra; Purva Khandelwal
Journal:  Indian J Anaesth       Date:  2009-10

4.  Update on transfusion solutions during surgery: review of hydroxyethyl starches 130/0.4.

Authors:  Ornella Piazza; Giuliana Scarpati; Rosalba Tufano
Journal:  Int J Gen Med       Date:  2010-10-05

5.  Ultrastructural changes, nuclear factor-kappaB activation, and tumor necrosis factor-alpha expression in brain after acute normovolemic hemodilution and controlled hypotension in rats.

Authors:  Ran Lv; Wei Zhou; Manlin Duan; Yali Ge; Taidi Zhong
Journal:  Croat Med J       Date:  2008-02       Impact factor: 1.351

Review 6.  CONTRA: Hydroxyethyl starch solutions are unsafe in critically ill patients.

Authors:  Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

7.  Administration of HES in elderly patients undergoing hip arthroplasty under spinal anesthesia is not associated with an increase in renal injury.

Authors:  Yuanyuan Zhang; Yonghao Yu; Junya Jia; Wenli Yu; Rubin Xu; Licheng Geng; Ying Wei
Journal:  BMC Anesthesiol       Date:  2017-02-21       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.